TrialCell reports. Medicine2024

Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).

Chao Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.